Trial Profile
A Phase 3, Randomized, Active-controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13vPnC Vaccine Compared With a 7vPnC in Healthy Infants in China
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Oct 2019
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 01 Nov 2019 Results assessing immunogenicity and safety of PCV13 compared with PCV7 in healthy infants in China were published in the Pediatric Infectious Disease Journal
- 31 May 2016 Primary endpoint (Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 3) has been met according to the results published in the Pediatric Infectious Disease Journal.
- 31 May 2016 Primary endpoint(Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series in Group 1 and Group 2) has been met according to the results published in the Pediatric Infectious Disease Journal.